For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...

NEW DELHI: The deadly cocktail of growing pollution and smog seems to be choking us immensely. Foracort, used for asthma and respiratory issues, has assumed the top slot in December in domestic pharma ...

New Delhi: As air pollution in most parts of northern India reaches extremely severe levels, choking residents and engulfing cities and towns in toxic smog, respiratory drug Foracort has become the ...

8yrold son on foracort inhaler for2 yrs,doc stopped inhaler, symtoms apeeared within 6 days ,now am giving him asthalin inhaler 4 times a day , should i start foracort and what are theside effects ...

Cipla Q2 FY26 Results: The India business generated Rs 3,146 crore in revenue, up 7 per cent YoY, led by solid traction in core therapies. Cipla’s respiratory brand Foracort retained its No. 1 ranking ...

In Jan, the Indian pharma market saw 8% growth driven by respiratory therapies. Anti-asthma drugs like Foracort had double-digit growth, reflecting pollution struggles. Acute and chronic segments also ...

The impact of air pollution on life expectancy is noteworthy, with an average Indian citizen losing 5.3 years due to air pollution. Indian respiratory therapy sales registered an upswing in January, ...